KRAS and colorectal carcinoma: We aimed to elucidate the prognostic association of the KRAS G12A substitution, relative to other KRAS mutations and KRAS wild-type, with RFS and OS in patients with stage II–III CRC who underwent surgery without neoadjuvant therapy.